BioCentury | Feb 9, 2015
Financial News

Summit proposes follow-on

Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Business: Musculoskeletal, Endocrine/Metabolic, Infectious Date announced: 2015-01-30 Type: Follow-on To be raised: Up to $40 million Shares: TBD Price prior: 127.5p Underwriters: JMP Securities; Oppenheimer; Needham Note: Summit plans...
BioCentury | Oct 2, 2014
Tools & Techniques

A CRISPR possibility for DMD

...exon skipping couldn't, such as larger, more complex deletions." Tinsley is CSO for DMD at Summit Corp. plc...
...the Netherlands PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Corp. plc...
BioCentury | Jul 21, 2014
Clinical News

SMT19969 regulatory update

...develop SMT19969 through clinical proof of concept to treat CDI (see BioCentury, Oct. 29, 2012). Summit Corp. plc...
BioCentury | Jul 14, 2014
Clinical News

SMT19969: Phase II started

...develop SMT19969 through clinical proof of concept to treat CDI (see BioCentury, Oct. 29, 2012). Summit Corp. plc...
BioCentury | Jun 30, 2014
Company News

Summit management update

Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Business: Musculoskeletal, Endocrine/Metabolic, Infectious Hired: Erik Ostrowski as CFO WIR Staff...
BioCentury | Mar 24, 2014
Clinical News

SMT19969: Phase II start

...program to develop SMT19969 through clinical proof-of-concept to treat CDI (see BioCentury, Oct. 29, 2012). Summit Corp. plc...
BioCentury | Mar 10, 2014
Financial News

Summit completes placing

Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Business: Musculoskeletal, Endocrine/Metabolic, Infectious Date completed: 3/4/14 Type: Placing Raised: £22 million ($36.8 million) Shares: 338.5 million Price: 6.5p Shares after offering: 821.2 million Investors: Existing investors WIR Staff...
BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

...BIOIMAGE-NMD consortium to develop imaging biomarkers for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) Summit Corp. plc...
BioCentury | Dec 16, 2013
Clinical News

SMT C1100: Phase Ib started

...that an "appropriate formulation" of SMT C1100 could continue development (see BioCentury, Aug. 9, 2010). Summit Corp. plc...
BioCentury | Dec 9, 2013
Company News

Summit, University of Oxford deal

...option to IP generated under the deal. The partners could not be reached for details. Summit Corp. plc...
Items per page:
1 - 10 of 109
BioCentury | Feb 9, 2015
Financial News

Summit proposes follow-on

Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Business: Musculoskeletal, Endocrine/Metabolic, Infectious Date announced: 2015-01-30 Type: Follow-on To be raised: Up to $40 million Shares: TBD Price prior: 127.5p Underwriters: JMP Securities; Oppenheimer; Needham Note: Summit plans...
BioCentury | Oct 2, 2014
Tools & Techniques

A CRISPR possibility for DMD

...exon skipping couldn't, such as larger, more complex deletions." Tinsley is CSO for DMD at Summit Corp. plc...
...the Netherlands PTC Therapeutics Inc. (NASDAQ:PTCT), South Plainfield, N.J. Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Summit Corp. plc...
BioCentury | Jul 21, 2014
Clinical News

SMT19969 regulatory update

...develop SMT19969 through clinical proof of concept to treat CDI (see BioCentury, Oct. 29, 2012). Summit Corp. plc...
BioCentury | Jul 14, 2014
Clinical News

SMT19969: Phase II started

...develop SMT19969 through clinical proof of concept to treat CDI (see BioCentury, Oct. 29, 2012). Summit Corp. plc...
BioCentury | Jun 30, 2014
Company News

Summit management update

Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Business: Musculoskeletal, Endocrine/Metabolic, Infectious Hired: Erik Ostrowski as CFO WIR Staff...
BioCentury | Mar 24, 2014
Clinical News

SMT19969: Phase II start

...program to develop SMT19969 through clinical proof-of-concept to treat CDI (see BioCentury, Oct. 29, 2012). Summit Corp. plc...
BioCentury | Mar 10, 2014
Financial News

Summit completes placing

Summit Corp. plc (LSE:SUMM), Abingdon, U.K. Business: Musculoskeletal, Endocrine/Metabolic, Infectious Date completed: 3/4/14 Type: Placing Raised: £22 million ($36.8 million) Shares: 338.5 million Price: 6.5p Shares after offering: 821.2 million Investors: Existing investors WIR Staff...
BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

...BIOIMAGE-NMD consortium to develop imaging biomarkers for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) Summit Corp. plc...
BioCentury | Dec 16, 2013
Clinical News

SMT C1100: Phase Ib started

...that an "appropriate formulation" of SMT C1100 could continue development (see BioCentury, Aug. 9, 2010). Summit Corp. plc...
BioCentury | Dec 9, 2013
Company News

Summit, University of Oxford deal

...option to IP generated under the deal. The partners could not be reached for details. Summit Corp. plc...
Items per page:
1 - 10 of 109